Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
Guardant Health's Capital Expenditure for the
three
months ended in Mar. 2022 was $-22.70 Mil. Its Revenue for the
three
months ended in Mar. 2022 was $96.10 Mil.
Hence, Guardant Health's Capex-to-Revenue for the
three
months ended in Mar. 2022 was 0.24.
Guardant Health Capex-to-Revenue Historical Data
The historical data trend for Guardant Health's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Guardant Health Annual Data
Trend
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Capex-to-Revenue
0.18
0.22
0.10
0.19
0.20
Guardant Health Quarterly Data
Dec16
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Capex-to-Revenue
0.12
0.20
0.23
0.23
0.24
Competitive Comparison
For the Diagnostics & Research subindustry, Guardant Health's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health Capex-to-Revenue Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Guardant Health's Capex-to-Revenue falls into.
Guardant Health Capex-to-Revenue Calculation
Guardant Health's Capex-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health (NAS:GH) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Guardant Health Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of Guardant Health's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
1.21(3.29%) Volume: 1,806,277 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:GH has been successfully added to your 
